Results 31 to 40 of about 1,580 (184)

Mavacamten as an Effective Treatment for HCM With Latent Exercise-Induced Obstruction: A Case Report. [PDF]

Case Rep Cardiol
Background Hypertrophic cardiomyopathy (HCM) is a myocardial disorder characterized by hypertrophy of the left ventricle that can lead to significant symptoms, particularly with exercise. For patients with HCM who demonstrate obstructive physiology, the first‐in‐class targeted cardiac specific myosin inhibitor, mavacamten, has been found to reduce the ...
Murthy N, Diep B, Evans J, Abramov D, Tran D.   +4 more
europepmc   +2 more sources

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy [PDF]

, 2023
Mavacamten is a first-in-class, targeted, cardiac-specific myosin inhibitor approved by the US Food and Drug Administration for the treatment of adults with symptomatic New York Heart Association Classes II and III obstructive hypertrophic cardiomyopathy
Elliott, Perry, Theodore P Abraham, Eugene Braunwald, Sara Saberi, Perry M Elliott, Saberi, Sara, Iacopo Olivotto, Abraham, Theodore, Braunwald, Eugene, Olivotto, Iacopo   +9 more
core   +3 more sources

Transitioning disopyramide to mavacamten in obstructive hypertrophic cardiomyopathy: A case series and clinical guide [PDF]

, 2023
BackgroundHypertrophic cardiomyopathy (HCM) is a genetic disorder for which first-line treatments for obstructive HCM (oHCM) include beta-blockers, non-dihydropyridine calcium channel blockers, and disopyramide for refractory cases.
Jorge Silva Enciso, Andrew Willeford, Enciso, Jorge Silva, Willeford, Andrew   +3 more
core   +1 more source

Mavacamten: A Novel Disease-Specific Treatment for Hypertrophic Cardiomyopathy

, 2023
Hypertrophic cardiomyopathy (HCM) is characterized by an abnormal thickening of the myocardium, leading to left ventricular outflow tract obstruction. Current treatments for HCM include non-disease-specific medications such as beta blockers or invasive ...
William H. Frishman, Capilupi, Michael J, Frishman, William H, Michael J. Capilupi   +3 more
core   +1 more source

Study design and rationale of EXPLORER-CN: a phase III, randomised, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy

BMJ Open, 2023
Introduction Hypertrophic cardiomyopathy (HCM) is a primary myocardial disease commonly caused by pathogenic genetic variants encoding sarcomere proteins.
Qing Zhang, Fang Wang, Yaling Han, Jing Sun, Shuyang Zhang, Wei Jin, Zhuang Tian, Ping Yang, Geng Wang, Jingmin Zhou, Peiwen Hsu   +10 more
doaj   +1 more source

Low-Dose Mavacamten Initiation in Obstructive Hypertrophic Cardiomyopathy: A Real-World Study in China. [PDF]

Cardiovasc Ther
Aims To evaluate the real‐world efficacy and safety of low‐dose (2.5 mg) mavacamten initiation in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Methods and Results This single‐center observational study (Zhongshan Hospital, China; Oct 2024–Apr 2025) enrolled 72 symptomatic oHCM patients (NYHA II/III, LVEF ≥ 55 ...
Yang W, Shi H, Chang RS, Zhang Y, Jixiang A, Wu C, Qian J, Ge J, Zhang S.   +8 more
europepmc   +2 more sources

Mavacamten for hypertrophic obstructive cardiomyopathy – Authors' reply [PDF]

The Lancet, 2021
reply to ...
Jacoby D., Ho C. Y., Lester S. J., Wang A., Olivotto I.   +4 more
openaire   +2 more sources

Is mavacamten superior to aficamten for hypertrophic cardiomyopathy? A frequentist network meta-analysis [PDF]

Exploration of Cardiology
Background: Myosin inhibitors have been shown to improve exercise capacity and symptoms, as well as reduce the left ventricular outflow tract (LVOT) gradient. This study explores the efficacy of mavacamten versus aficamten in hypertrophic cardiomyopathy (
Ayesha Aman, Bisma Akram, Arfa Akram, Momina Maham, Eisha Tariq, Aimen Hassan, Masooma Zainab Bokhari, Aleena Akram, Sania Akram, Malik Waleed Zeb Khan   +9 more
doaj   +1 more source

Effect of chronopharmacology and food on in vivo pharmacokinetic profile of mavacamten: supplementary materials

, 2023
Aim: This study investigated the impact of food intake and circadian rhythms on the pharmacokinetics of mavacamten. Materials & methods: A sensitive bioanalytical method for quantifying mavacamten in rat plasma was developed and validated. Thismethod was
Siva Nageswara Rao Gajula (15995481), Manoj P Dandekar (15995488), Ziaur Rahman (390962), Sasikala Talari (15995482), Rajesh Sonti (1831000), Vijay Munjal (15995485), Tanaaz Navin Nathani (15995483)   +6 more
core   +1 more source

Long‐Term Efficacy and Safety of Mavacamten in Chinese Patients With Obstructive Hypertrophic Cardiomyopathy: Week 78 Results From the EXPLORER‐CN Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Long‐term efficacy and safety of mavacamten in Chinese patients with obstructive hypertrophic cardiomyopathy are unknown. Methods Patients who completed the 30‐week, double‐blind, placebo‐controlled treatment period in EXPLORER‐CN (A Study to ...
Zhuang Tian, Xiaoyan Li, Liwen Li, Qing Zhang, Jian’an Wang, Yunqi Shi, Daoquan Peng, Wei Ma, Ping Yang, Xiang Cheng, Wei Jin, Fang Wang, Yimeng Xie, Beth Pan, Victoria Florea, Shuyang Zhang   +15 more
doaj   +1 more source